Evaluation of the Effect of Paclitaxel, Epirubicin and Tamoxifen by Cell Kinetics Parameters in Estrogen-Receptor-Positive Ehrlich Ascites Tumor (Eat) Cells Growing in vitro
In this study the antiproliferative effects of Paclitaxel (PAC), Epirubicin (EPI) and Tamoxifen (TAM) on growth kinetics of Ehrlich Ascites Tumor (EAT) cells were examined in culture. An estrogen-receptor-positive ER (+) hyperdiploid EAT cell line growing in vitro was also analysed in the present study. IC50 doses of PAC, EPI and TAM (12 μg/ml, 12 μg/ml and 2 μg/ml, respectively) were used. Cells were treated with the above doses for 0, 4, 8, 16, 24 and 32 hrs. At the end of these periods, living cell numbers were determined by collecting EAT cells in every group for growth study rate and for MTT assay. Therefore, the mitotic index was determined in the same experimental groups. The proliferation of EAT cells, inhibited by PAC, EPI and TAM concentrations was compared to control with increasing treatment time (4–32 hrs). Treatment of PAC, EPI and TAM alone for 24 hrs decreased the proliferation rate of EAT cells by 50% with respect to control. The inhibition of proliferation rate was higher in double drug treatment than that in single drug treatment with increased treatment time. In the treatment of three drugs applied for 32 hrs, this effect reached a maximum and proliferation rate decreased by 12% as compared to the (100%) control. In our studies, when the mitotic index parameter data were evaluated to determine which phase of the cell cycle was affected by PAC to cause the repression of cell reproduction, it was found that PAC exerted of its cytotoxic effect by causing cell accumulation at mitosis. The accumulation of the cells resulted in an increase in mitotic index values, which was an expected consequence of PAC treatment. It was observed that depending on the drug treatments, inhibition of proliferation rate and mitotic index in EAT cells were increased with respect to control, being with statistically significant occurrence (p < 0.01 - p < 0.001). As a result, concomitant treatment combined with hormonal therapy has given improved results compared with single treatment and PAC+EPI+TAM treatments had a maximum synergistic effect for 32 hrs (p < 0.001).
KeywordsEAT cells cell kinetics Paclitaxel Epirubicin Tamoxifen
Unable to display preview. Download preview PDF.
This work was supported by the Research Fund of Istanbul University. Project no: B-757/12092000.
- 3.Cuzick, J., Baum, M. (1985) Tamoxifen and contralateral breast cancer. Lancet 2 (8449), 282.Google Scholar
- 17.Norton, L., Seidman, A. (1992) Taxol plus recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. 2nd Natl. Cancer Inst. Workshop on Taxol and Taxus, Alexandria VA., pp. 23-24.Google Scholar
- 18.Osborne, C. K. (1994) Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. Long term tamoxifen for breast cancer. In: Jordan, V. C. (ed.) Long Term Tamoxifen for Breast Cancer. Wisconsin University Press, Madison., pp. 181–198.Google Scholar
- 22.Özcan Arıcan, G., Topçul, M. R. (2003) Effect of epirubicin on mitotic index in cultured L-cells. J. Cell and Molecular Biol. 2, 43–48.Google Scholar
- 28.Schiff, P. B., Horwitz S. B. (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Cell Biol. 77, 1561–1565.Google Scholar
- 29.Stewart, H. L., Snell, K. C., Dunham, L. J., Schleyen, S. M. (1959) V2 carcinoma, rabbit. In: Atlas of Tumor Pathology, Transplantable and Transmissible Tumors of Animals. Section XII, fascicle 40. AFIP, Washington D. C., pp. 38–42.Google Scholar
- 32.Zar, J. H. (1984) Biostatistical Analysis. 2nd Edition. Prentice-Hall Inc, Englewood Cliffs, New Jersey.Google Scholar
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.